Figure 3:

Sample case: Targeted sequencing of EGFR transcript.(A) Polymorphism results. The two expected nucleotide substitutions are silent: G>A (CAG>CAA = Gln) at position 55 181 370 and T>C (ACT>ACC = Thr) at position 55 198 724; two other substitutions at position 55 181 378 (C>T leading to the amino acid change T745M) and at position 55 191 822 (T>G leading to the amino acid change L813R) are responsible for the sensitivity to anticancer drugs, in particular, to gefitinib and erlotinib [38]. (B) Nucleotide plot. The zoom-out scheme at the bottom depicts seven alignment picks; they represent seven sequenced exons of the transcript. The nucleotide plot is showing the first of these picks, pointed to by the orange arrows.